Clinical Potential of Aldose Reductase Inhibitors in Diabetic Neuropathy

Kinoshita JH, Merola LO, Satoh K, et al. Osmotic changes caused by accumulation of dulcitol in the lenses of rats fed with galactose. Nature 1962; 194:1085–7 Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599–606 Williamson JR, Cheng K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801–13 Kashiwagi A, Asahina T, Ikebuchi M, et al. Abnormal glutathione metabolism and increased cytotoxicity caused by H2O2 in human umbilical vein endothelial cells cultured in high glucose medium. Diabetologia 1994; 37: 262–9 Stevens MJ, Dananberg J, Feldman EL, et al. The linked roles of nitric oxide, aldose reductase and, (Na+, K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94: 853–9 Obrosova IG, Van Huysen C, Fathallah L, et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16: 123–5 Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999; 13: 23–30 Petersen A, Kappler F, Szwergold BS, et al. Fructose metabolism in the human erythrocyte: phosphorylation to fructose 3-phosphate. Biochem J 1992; 284 (Pt 2): 363–6 Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates: investigation using a specific assay for methylglyoxal. Eur J Biochem 1993; 212: 101–5 Hamada Y, Odagaki Y, Sakakibara F, et al. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients. Life Sci 1995; 57: 23–9 King GL, Ishii H, Koya D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int Suppl 1997; 60: S77–85 Cameron NE, Cotter MA, Jack AM, et al. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999; 42: 1120–30 Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090–5 Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46Suppl. 2: S31–7 Handelsman DJ, Turtle JR. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 1981; 30: 459–64 Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy: a clinical and neurophysiological study. J Neurol Neurosurg Psychiatry 1981; 44: 991–1001 Jaspan J, Maselli R, Herold K, et al. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 1983; II(8353): 758–62 Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983; 308: 119–25 Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983; 32: 938–42 Lewin IG, O’Brien IA, Morgan MH, et al. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia 1984; 26: 445–8 Christensen JE, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study. Acta Neurol Scand 1985; 71: 164–7 Fagius J, Brattberg A, Jameson S, et al. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985; 28: 323–9 Lehtinen JM, Hyvonen SK, Uusitupa M, et al. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy. J Neurol 1986; 233(3): 174–7 Jaspan J. Pharmacological inhibition of aldose reductase in human diabetic neuropathy. Drugs 1986; 32Suppl. 2: 23–9 Martyn CN, Reid W, Young RJ, et al. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy: failure to improve abnormal nerve function. Diabetes 1987; 36: 987–90 Sima AA, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988; 319: 548–55 Guy RJ, Gilbey SG, Sheehy M, et al. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia 1988; 31: 214–20 O’Hare JP, Morgan MH, Alden P, et al. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year’s treatment with sorbinil. Diabetic Med 1988; 5: 537–42 Jennings PE, Nightingale S, Le Guen C, et al. Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy. Diabetic Med 1990; 7: 63–8 Sima AA, Nathaniel V, Prashar A, et al. Endoneurial microvessels in human diabetic neuropathy: endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor. Diabetes 1991; 40: 1090–9 Sima AA, Prashar A, Nathaniel V, et al. Overt diabetic neuropathy: repair of axoglial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabetic Med 1993; 10: 115–21 Sorbinil Retinopathy Trial Research Group. The sorbinil retinopathy trial: neuropathy results. Neurology 1993; 43: 1141–9 Boulton AJ, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990; 33: 431–7 van Gerven JM, Lemkes HH, van Dijk JG. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy. J Diabet Complications 1992; 6: 45–8 Macleod AF, Boulton AJ, Owens DR, et al. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy: North European Tolrestat Study Group. Diabete Metab 1992; 18: 14–20 Santiago JV, Snksen PH, Boulton AJ, et al. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabet Complications 1993; 7: 170–8 Giugliano D, Marfella R, Quatraro A, et al. Tolrestat for mild diabetic neuropathy: a 52-week, randomized, placebo-controlled trial. Ann Intern Med 1993; 118: 7–11 Sima AA, Greene DA, Brown MB, et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy: the Tolrestat Study Group. J Diabet Complications 1993; 7: 157–69 Giugliano D, Acampora R, Marfella R, et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995; 18: 536–41 Fabiani F, De Vincentis N, Staffilano A. Effect of tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy. Diabete Metab 1995; 21: 360–4 Nicolucci A, Carinci F, Graepel JG, et al. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy: a meta-analysis of individual patient data. Diabetes Care 1996; 19: 1091–6 Didangelos TP, Karamitsos DT, Athyros VG, et al. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. J Diabet Complications 1998; 12: 201–7 Gill JS, Williams G, Ghatei MA, et al. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabete Metab 1990; 16: 296–302 Young RJ, Martyn CN, Clarke BF, et al. Preliminary observations on the use of the aldose reductase inhibitor drug ponalrestat in diabetic neuropathy. Diabetes Nutr Metab Clin Exp 1991; 4: 287–92 Ziegler D, Mayer P, Rathmann W, et al. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 1991; 14: 63–73 Salmon P, Perkins CM, Tomkin GH. Diabetic neuropathy and aldose reductase inhibition. Diabetes Nutr Metab Clin Exp 1991; 4: 135–9 Florkowski CM, Rowe BR, Nightingale S, et al. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 1991; 40: 129–33 Sundkvist G, Armstrong FM, Bradbury JE, et al. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months: United Kingdom/Scandinavian Ponalrestat Trial. J Diabet Complications 1992; 6: 123–30 Krentz AJ, Honigsberger L, Ellis SH, et al. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabetic Med 1992; 9: 463–8 Faes TJ, Yff GA, DeWeerdt O, et al. Treatment of diabetic autonomie neuropathy with an aldose reductase inhibitor. J Neurol 1993; 240: 156–60 Boland OM, Blackwell CC, Clarke BF, et al. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Diabetes 1993; 42: 336–40 Stracke H, Dietrich E. Influence of ponalrestat, an aldose-reductase inhibitor, on diabetic polyneuropathy. Medizinische Welt 1994; 45: 84–9 Goto Y, Hotta N, Shigeta Y, et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy: clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 1995; 49: 269–77 Hotta N, Sakamoto N, Shigeta Y, et al. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabet Complications 1996; 10: 168–72 Nakayama M, Nakamura J, Hamada Y, et al. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care 2001; 24: 1093–8 Arezzo JC, Klioze SS, Peterson MJ, et al. Efficacy and safety results of a phase II multicenter study of the aldose reductase inhibitor zopolrestat in patients with peripheral symmetrical diabetic polyneuropathy [abstract]. Diabetes 1996; 45Suppl. 2: 276A Greene DA, Arezzo JC, Brown MB, et al. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999; 53: 580–91 Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001; 24: 1776–82 Foppiano M, Lombardo G. Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet 1997; 349: 399–400 Greene DA, Sima AA. Effects of aldose reductase inhibitors on the progression of nerve damage. Diabet Med 1993; 10 Suppl. 2: 31S–2S Utsunomiya K, Narabayashi I, Nakatani Y, et al. TI I–123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy. Clin Nucl Med 1999; 24(6): 418–20 Ishii A, Kotani T, Nagaki Y, et al. Highly selective aldose reductase inhibitors: 1. 3-(arylalkyl)-2,4,5-trioxoimidazolidine-l-acetic acids. J Med Chem 1996; 39: 1924–7 Hohman TC, Meng XU, Tse S, et al. The ARI-509 development team: enhanced biochemical efficacy of the novel aldose reductase inhibitor, ARI-509, in human tissues [abstract]. Diabetes 1996; 45Suppl. 2: 5A Kurono M, Fujiwara I, Yoshida K. Stereospecific interaction of a novel spirosuc-cinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. Biochemistry 2001; 40: 8216–26 Nicolucci A, Carinci F, Cavaliere D, et al. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy: the Italian Study Group. The St Vincent Declaration. Diabetic Med 1996; 13: 1017–26 Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46Suppl. 2: S82–9 Dyck PJ, Zimmerman BR, Vilen TH, et al. Nerve glucose, fructose, sorbitol, myoinositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988; 319: 542–8 Kaul CL, Ramarao P. The role of aldose reductase inhibitors in diabetic complications: recent trends. Methods Find Exp Clin Pharmacol 2001; 23: 465–75 Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med 1999; 107(2B): 9S–16S Valensi P, Attali JR, Gagant S. Reproducibility of parameters for assessment of diabetic neuropathy: the French Group for Research and Study of Diabetic Neuropathy. Diabetic Med 1993; 10: 933–9 Stevens MJ. New imaging techniques for cardiovascular autonomic neuropathy: a window on the heart. Diabetes Technol Ther 2001; 3: 9–22 Malone JI, Leavengood H, Peterson MJ, et al. Red blood cell sorbitol as an indicator of polyol pathway activity: inhibition by sorbinil in insulin-dependent diabetic subjects. Diabetes 1984; 33: 45–9 Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Exp Opin Investig Drugs 1999; 8: 2095–119 Hamada Y, Kitoh R, Raskin P. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus. Diabetic Med 1993; 10: 33–8 Nishimura C, Hamada Y, Tachikawa T, et al. Enzyme immunoassay for erythrocyte aldose reductase. Clin Chem 1994; 40: 889–94 Hamada Y, Kitoh R, Raskin P. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 1991; 40: 1233–40 Hamada Y, Nishimura C, Koh N, et al. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients. Diabetes Care 1998; 21: 1014–8 Takahashi Y, Tachikawa T, Ito T, et al. Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control. Diabetes Res Clin Pract 1998; 42 Suppl.: 101–7 Ko BC, Lam KS, Wat NM, et al. An (A–C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995; 44: 727–32 Heesom AE, Hibberd ML, Millward A, et al. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 1997; 46: 287–91 Kao YL, Donaghue K, Chan A, et al. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes 1999; 48: 1338–40 Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998; 64: 213–6 Yobe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21–33 Hamada Y, Nakamura J, Naruse K, et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539–44 Tsukushi S, Katsuzaki T, Aoyama I, et al. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Kidney Int 1999; 55: 1970–6 Sato K, Inazu A, Yamaguchi S, et al. Monkey 3-deoxyglucosone reductase: tissue distribution and purification of three multiple forms of the kidney enzyme that are identical with dihydrodiol dehydrogenase, aldehyde reductase, and aldose reductase. Arch Biochem Biophys 1993; 307: 286–94 Correspondence and offprints: Dr Yoji Hamada, Division of Metabolic Diseases, Nagoya University Graduate School of Medicine, 65-Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan. E-mail: [email protected]